• With experience in cGMP vector manufacturing
    Global CRO/CDMO Service Provider of GMP-Grade Retroviral vector(RVV)
  • One-Stop CRO/CDMO Service for Cell&Gene Therapy
    From Process Development To GMP Manufacturing
  • The world's leading CRO/CDMO service platform
    Solving the challenges of high cost and low manufacturing capacity in the CGT industry
  • CRO/CDMOservices, One-Stop solution provider
    Make R&D Easier For Lab and Biotech/Pharma Companies!
  • The leader of PackRV-SS ® &eVLP gene editing
    Advanced Vector Design, Manufacturing,and Gene Delivery Technology Platform
Company Profile
Company Profile
Shenzhen Cell Valley Biopharmaceutical Co., Ltd. (SZCV) is a one-stop CRO/CDMO service platform dedicated to the field of cell and gene therapy, as well as an integrated platform for the clinical translation and application of new biomedical technologies. The company was jointly founded by a team of returnee scientists from Harvard University, Cornell University, Columbia University, and the University of California, San Diego. SZCV focuses on core technologies including viral vectors, cell therapeutics, exosomes, and eVLP delivery systems, and possesses full-process capabilities from process development and GMP manufacturing to quality control. As a major public service platform for the biomedical industry in Shenzhen, its flagship project, the “One-stop Cell and Gene Therapy CRO/CDMO Service Platform – South China Cell Factory,” was selected as a 2022 Shenzhen Major Project. SZCV is also recognized as a Shenzhen Overseas High-level Talent Team, a Viral Vector Common Technology Research Platform under the National Engineering Research Center for Key Generic Technologies in the Cell Industry, a Commercialization Base of Shenzhen High-tech Zone Innovation Achievements Program, and serves as the Vice Chairman Unit of the Shenzhen Biomedical Industry-Education Alliance.
  • 10000 10000 m2
    Manufacturing
    &Office area
  • 7000 7000 m2
    ‘C+A’‘B+A’ cleanroom
  • 198 198 th
    Cooperative partner
  • 38 38 th
    Technical patent

Focus on Cell Therapy • Pilot the Healthy Future

Shenzhen Cell Valley Biopharmaceuticals Co., LTD. (hereinafter referred to as Shenzhen Cell Valley) is a one-stop comprehensive outsourcing service provider focusing on the field of cell and gene therapy industry (CGT) in China, and is the only CRO/CDMO company with clinical grade retroviral vector GMP industrial production in China.

Cooperative Partner

  • ludaopei
    ludaopei
  • beida
    beida
  • Huaneng Group
    Huaneng Group
  • qinghua
    qinghua
  • beidayanjiuyaun
    beidayanjiuyaun
  • hauzhongkejida
    hauzhongkejida
  • zhongkeyuan
    zhongkeyuan
  • BaoAn
    BaoAn
  • DianZi
    DianZi
  • heyuan
    heyuan
  • 北大深圳医院
    北大深圳医院
  • 广东妇幼
    广东妇幼
  • 华中协和
    华中协和
  • hk
    hk
  • 广医科大一院
    广医科大一院
  • 深圳药检
    深圳药检
  • 中科大
    中科大
  • 深职大
    深职大
  • 中山大学五院
    中山大学五院
  • 湖北干细胞库
    湖北干细胞库
  • 科诺
    科诺
  • 科医创联
    科医创联
About Us
Official WeChat AccountOfficial WeChat Account
Contact Us
400-800-1266

Contact:Miss Sun

Mobile:+86 18810616095

Email:sunrui@sz-cell.com

Address:No.1 Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen

Bottom Navigation
Shenzhen Cell Valley Biopharmaceutical Co., Ltd.​​ is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.